BCL2 and breast carcinoma: In breast cancer, UBE2C knockdown increased the sensitivity of cancer cells to epirubicin and docetaxel and promoted the apoptosis induced by these two drugs through impaired the increased BCL-2 and MDR-1 expression levels [20].